Methotrexate

Children with Cogan’s syndrome should undergo thorough evaluations upon presentation, including screenings for autoimmune and infectious diseases, as well as echocardiography and brain MRI, according to data.

Patients with rheumatoid arthritis who demonstrate lower disease activity are more likely to remain in LDA or remission after switching from combination therapy to monotherapy, according to data published in the Journal of Rheumatology.

In a panel-led project, 23 experts created a comprehensive guide for the long-term management of inflammatory skin diseases in pediatric patients treated with methotrexate.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discussed some of the biggest challenges in treating rheumatoid arthritis, including issues with infections and other comorbidities.

Patients with rheumatoid arthritis who have lower disease activity are more likely to remain in remission after switching from combination therapy to monotherapy, according to data published in The Journal of Rheumatology.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.

DESTIN, Fla. — Complicated disease pathogenesis and a lack of FDA-approved therapies makes sarcoidosis a significant clinical challenge, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.